Diamyd Medical's Diamyd (rhGAD65/alum) receives Fast Track designation for type 1 diabetes treatment in paediatric patients

Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA

Neurocrine Biosciences launches swallow-friendly option for tardive dyskinesia and Huntington's disease chorea treatment

Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review

Atara Biotherapeutics gains FDA Priority Review for tabelecleucel

Hyperfine secures FDA clearance for faster brain imaging software

Silo Pharma agrees Alzheimer's drug licence

Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation

Camurus reports positive Phase 3 ACROINNOVA 2 results

Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI

GRAIL, Inc. updates on PATHFINDER 2 and NHS-Galleri trials

AbbVie submits Upadacitinib applications to FDA and EMA for new indication

Emmaus Life Sciences receives 'No Action Indicated' classification from FDA for PADE compliance programme

Mabwell receives fast track designation from FDA for 9MW2821

Genedrive receives FDA Breakthrough Device Designation for infant hearing loss test